Natixis Partners advised Cenexi shareholders and its management team in the sale of a majority stake to Gland Pharma Limited, an Indian pharmaceutical Group held by Fosun Pharmaceuticals. This transaction allows Cathay Capital, the majority shareholder to divest 100% of its stake

Based in Fontenay-sous-Bois (Paris region), Cenexi was created in 2008 from a spin-off transaction of Roche Group. Over the years, Cenexi has become a leading CDMO player in Europe with deep expertise in complex and high-value added sterile forms such as ampoules dedicated to hospitals on which the Group is positioned as a major European player, pre filled syringes, vials and other complex or niche dosage forms. Cenexi has developed an agile, end-to-end CDMO service offering, from development to finished dosage production and packaging, covering the whole value chain. The Group relies on 4 complementary industrial sites based in France and Belgium for its manufacturing ; all of them benefitting from a large range of certifications (FDA, ANSM, ANVISA, PMDA, etc.). Thanks to the strong quality of its industrial tool coupled to a recognized know-how , Cenexi serves a large portfolio of more than 100 clients with diversified profiles from big phamas to biotechs covering more than 120 countries. The acquisition by Gland Pharma Limited will reinforce Cenexi’s international exposure by becoming the bridgehead of the Indian pharmaceutical group in Europe